Research advances in CMR for mitral valve apparatus abnormalities in hypertrophic cardiomyopathy

Share this content in WeChat

[Chinese] [PDF] 31 2

• Review •

LU Jiahui YANG Na CHEN Zixian

Cite this article as: LU J H, YANG N, CHEN Z X. Research advances in CMR for mitral valve apparatus abnormalities in hypertrophic cardiomyopathy[J]. Chin J Magn Reson Imaging, 2026, 17(4): 175-183. DOI:10.12015/issn.1674-8034.2026.04.025.

Abstract

[Abstract] Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disorder caused by mutations in genes encoding sarcomeric proteins. Its pathophysiological hallmarks include left ventricular hypertrophy and left ventricular outflow tract obstruction (LVOTO). While septal thickening constitutes the primary anatomical basis of LVOTO, structural and functional abnormalities of the mitral valve apparatus play an equally critical role in the obstruction mechanism and symptom exacerbation: a factor often underestimated in clinical practice. Cardiac magnetic resonance (CMR), leveraging its high spatial resolution and multi-planar imaging capabilities, has emerged as a pivotal imaging modality for evaluating the morphology and function of the mitral valve apparatus in HCM patients. However, existing reviews primarily focus on the application of CMR in assessing the overall characteristics and myocardial tissue of HCM, and there is a lack of systematic summaries of its role in mitral valve apparatus abnormalities. In particular, there is still a gap in in-depth analysis of the association between morphological changes and the mechanisms of LVOTO. Therefore, aiming to enhance clinicians' understanding of mitral valve apparatus abnormalities and provide imaging evidence for early intervention and individualized treatment of the disease, this review systematically summarizes recent advances in CMR for assessing mitral valve abnormalities in HCM, analyzes the current research issues, and proposes future research directions, aiming to enhance clinicians' understanding of these anomalies and provide imaging evidence for early intervention and individualized medicine.

[Keywords] hypertrophic cardiomyopathy；mitral valve apparatus；left ventricular outflow tract obstruction；cardiac magnetic resonance；magnetic resonance imaging；individualized medicine

Contributor Information

LU Jiahui¹ YANG Na² CHEN Zixian^{1,
2*}

¹ The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China

² Departmment of Radiology, the First Hospital of Lanzhou University, Lanzhou 730000, China

Corresponding author: CHEN Z X, E-mail: chenzxcmr@163.com

Conflicts of interest None.

Publication Information

Received 2025-12-29

Accepted 2026-03-09

DOI: 10.12015/issn.1674-8034.2026.04.025

Text

References

[1]

MÖBIUS-WINKLER M N, LAUFS U, LENK K. The diagnosis and treatment of hypertrophic cardiomyopathy[J]. Dtsch Arztebl Int, 2024, 121(24): 805-811. DOI: 10.3238/arztebl.m2024.0196.

[2]

CUI H, LAI Y Q. Mitral valve in hypertrophic obstructive cardiomyopathy: Status and controversy[J]. J Clin Surg, 2023, 31(9): 804-807. DOI: 10.3969/j.issn.1005-6483.2023.09.002.

[3]

SAKELLAROPOULOS S, SVAB S, MOHAMMED M, et al. The role of mitral valve in hypertrophic obstructive cardiomyopathy: an updated review[J/OL]. Curr Probl Cardiol, 2021, 46(3): 100641 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/32586596/. DOI: 10.1016/j.cpcardiol.2020.100641.

[4]

HERMIDA U, STOJANOVSKI D, RAMAN B, et al. Left ventricular anatomy in obstructive hypertrophic cardiomyopathy: beyond basal septal hypertrophy[J]. Eur Heart J Cardiovasc Imaging, 2023, 24(6): 807-818. DOI: 10.1093/ehjci/jeac233.

[5]

KLUES H G, MARON B J, DOLLAR A L, et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy[J]. Circulation, 1992, 85(5): 1651-1660. DOI: 10.1161/01.cir.85.5.1651.

[6]

MARON M S, OLIVOTTO I, HARRIGAN C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy[J]. Circulation, 2011, 124(1): 40-47. DOI: 10.1161/CIRCULATIONAHA.110.985812.

[7]

Imaging Group of the Cardiovascular Disease Branch of the Chinese Medical Association, Cardiovascular Professional Committee of the Radiology Branch of the Chinese Medical Association. Chinese expert consensus on the clinical appropriate use criteria of non-invasive cardiovascular imaging modalities[J]. Chin J Cardiol, 2020, 48(11): 906-921. DOI: 10.3760/cma.j.cn112148-20200413-00309.

[8]

GARBIN H I, FOPPA M, BIOLO A, et al. Left atrial late gadolinium enhancement and atrial fibrillation in hypertrophic cardiomyopathy[J/OL]. Heart Rhythm, 2025, 22(12): e1241-e1247 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/40784418/. DOI: 10.1016/j.hrthm.2025.08.008.

[9]

ZHI Y, ZHANG T Y, GUI F D, et al. Myocardial fibrosis evaluated by T1 mapping and its relationship to left ventricular hypertrophy, strain, and T2 value in hypertrophic cardiomyopathy without late gadolinium enhancement[J/OL]. J Thorac Imaging, 2025 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/41084187/. DOI: 10.1097/RTI.0000000000000862.

[10]

SONG Y Y, LU M J, ZHAO S H. Application progresses of cardiovascular MRI in mitral valve diseases[J]. Chin J Med Imaging Technol, 2024, 40(2): 290-293. DOI: 10.13929/j.issn.1003-3289.2024.02.028.

[11]

TANG Y Q, NUERLAN N, MAIMAITI YIMING D. Research progress in the diagnosis and treatment of HCM[J]. Adv Clin Med, 2023, 13(9): 14695-14700. DOI: 10.12677/ACM.2023.1392054.

[12]

YANG Y L, LUO X Y, LUO R H, et al. Application and progress of cardiac magnetic resonance quantitative technology in the evaluation of myocardial lesions[J]. J Chin Physician, 2024, 26(1): 1-5. DOI: 10.3760/cma.j.cn431274-20240101-00001.

[13]

POPA M O, IRIMIA A M, PAPAGHEORGHE M N, et al. The mechanisms, diagnosis and management of mitral regurgitation in mitral valve prolapse and hypertrophic cardiomyopathy[J/OL]. Discoveries (Craiova), 2016, 4(2): e61 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/32309580/. DOI: 10.15190/d.2016.8.

[14]

RICCI F, AUNG N, GALLINA S, et al. Cardiovascular magnetic resonance reference values of mitral and tricuspid annular dimensions: the UK Biobank cohort[J/OL]. J Cardiovasc Magn Reson, 2020, 23(1): 5 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/33407573/. DOI: 10.1186/s12968-020-00688-y.

[15]

TUMENAS A, TAMKEVICIUTE L, ARZANAUSKIENE R, et al. Multimodality imaging of the mitral valve: morphology, function, and disease[J]. Curr Probl Diagn Radiol, 2021, 50(6): 905-924. DOI: 10.1067/j.cpradiol.2020.09.013.

[16]

LAM J H C, RANGANATHAN N, WIGLE E D, et al. Morphology of the human mitral valve: I. chordae tendineae: a new classification[J]. Circulation, 1970, 41(3): 449-458. DOI: 10.1161/01.cir.41.3.449.

[17]

MAFFESSANTI F, GRIPARI P, PONTONE G, et al. Three-dimensional dynamic assessment of tricuspid and mitral annuli using cardiovascular magnetic resonance[J]. Eur Heart J Cardiovasc Imaging, 2013, 14(10): 986-995. DOI: 10.1093/ehjci/jet004.

[18]

KHALIGHI A H, DRACH A, BLOODWORTH C H 4th, et al. Mitral valve chordae tendineae: topological and geometrical characterization[J]. Ann Biomed Eng, 2017, 45(2): 378-393. DOI: 10.1007/s10439-016-1775-3.

[19]

SABBAG A, ESSAYAGH B, BARRERA J D R, et al. EHRA expert consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex in collaboration with the ESC Council on valvular heart disease and the European Association of Cardiovascular Imaging endorsed cby the Heart Rhythm Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart Rhythm Society[J]. Europace, 2022, 24(12): 1981-2003. DOI: 10.1093/europace/euac125.

[20]

JEDRZEJCZYK J H, CARLSON HANSE L, JAVADIAN S, et al. Mitral annular forces and their potential impact on annuloplasty ring selection[J/OL]. Front Cardiovasc Med, 2021, 8: 799994 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/35059450/. DOI: 10.3389/fcvm.2021.799994.

[21]

CALAFIORE A M, PRAPAS S, TOTARO A, et al. Cutting the second order chords during mitral valve repair[J]. J Card Surg, 2022, 37(12): 4072-4078. DOI: 10.1111/jocs.17194.

[22]

NEEMA P K, PANIDAPU N. The mechanisms and pathophysiology of mitral regurgitation: a narrative review[J]. Ann Card Anaesth, 2025, 28(2): 109-118. DOI: 10.4103/aca.aca_221_24.

[23]

RAJIAH P, FULTON N L, BOLEN M. Magnetic resonance imaging of the papillary muscles of the left ventricle: normal anatomy, variants, and abnormalities[J/OL]. Insights Imaging, 2019, 10(1): 83 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/31428880/. DOI: 10.1186/s13244-019-0761-3.

[24]

MARON M S, ROWIN E J, MARON B J. How to image hypertrophic cardiomyopathy[J/OL]. Circ Cardiovasc Imaging, 2017, 10(7): e005372 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/28701526/. DOI: 10.1161/CIRCIMAGING.116.005372.

[25]

LI B L, XIE L, LI Y J, et al. Mitral valve management in hypertrophic obstructive cardiomyopathy and its controversies[J]. Chin J Clin Thorac Cardiovasc Surg, 2024, 31(8): 1242-1248. DOI: 10.7507/1007-4848.202312036.

[26]

SEITLER S, DE ZOYSA ANTHONY S, OBIANYO C C C, et al. Systolic anterior motion of the anterior mitral valve leaflet begins in subclinical hypertrophic cardiomyopathy[J]. Eur Heart J Cardiovasc Imaging, 2023, 25(1): 86-94. DOI: 10.1093/ehjci/jead186.

[27]

FAVA A M, MEHTA A R, BAUER A, et al. Measurements of the interventricular septum and mitral leaflet length in hypertrophic cardiomyopathy patients who underwent surgical myectomy: a prospective comparative multimodality imaging study[J/OL]. Am J Cardiol, 2024, 227: 48-56 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/39094946/. DOI: 10.1016/j.amjcard.2024.07.034.

[28]

LENTZ CARVALHO J, SCHAFF H V, MORRIS C S, et al. Anomalous papillary muscles-Implications in the surgical treatment of hypertrophic obstructive cardiomyopathy[J/OL]. J Thorac Cardiovasc Surg, 2022, 163(1): 83-89.e1 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/32414597/. DOI: 10.1016/j.jtcvs.2020.04.007.

[29]

GUIGUI S A, TORRES C, ESCOLAR E, et al. Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review[J]. J Thorac Dis, 2022, 14(6): 2309-2325. DOI: 10.21037/jtd-22-182.

[30]

SAHOTA M, SARASKANI S R, XU H, et al. Machine learning evaluation of LV outflow obstruction in hypertrophic cardiomyopathy using three-chamber cardiovascular magnetic resonance[J]. Int J Cardiovasc Imaging, 2022, 38(12): 2695-2705. DOI: 10.1007/s10554-022-02724-7.

[31]

GAO Y M, DUAN F J, PANG K J, et al. Changes on the prolonged leaflets and abnormal tenting morphology of mitral valve in patients with hypertrophic obstructive cardiomyopathy post septal myectomy[J]. Chin Circ J, 2020, 35(4): 379-383. DOI: 10.3969/j.issn.1000-3614.2020.04.011.

[32]

USUI A, MUTSUGA M. Surgical management for systolic anterior motion (SAM) of the mitral valve in obstructive hypertrophic myopathy[J]. Ann Thorac Cardiovasc Surg, 2022, 28(4): 239-248. DOI: 10.5761/atcs.ra.22-00103.

[33]

WU Z H, XIE L, LI Y J, et al. Mitral valve in obstructive hypertrophic cardiomyopathy: abnormalities, management and controversies[J/OL]. Rev Cardiovasc Med, 2023, 24(9): 246 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/39076404/. DOI: 10.31083/j.rcm2409246.

[34]

TROY A L, NARULA N, MASSERA D, et al. Histopathology of the mitral valve residual leaflet in obstructive hypertrophic cardiomyopathy[J/OL]. JACC Adv, 2023, 2(3): 100308 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/37383048/. DOI: 10.1016/j.jacadv.2023.100308.

[35]

OGUNMUYIWA O, RELLECKE P, LICHTENBERG A, et al. Muscular mitral chord contribution to left ventricular outflow tract obstruction in HOCM[J/OL]. Thorac Cardiovasc Surg Rep, 2019, 8(1): e18-e19 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/31211027/. DOI: 10.1055/s-0039-1692155.

[36]

HAYASHI H, SINGH S K, HAHN R T, et al. Mitral regurgitation mechanisms related to systolic anterior motion in hypertrophic cardiomyopathy[J]. J Thorac Dis, 2024, 16(1): 26-39. DOI: 10.21037/jtd-23-1206.

[37]

GHARIBEH L, SMEDIRA N G, GRAU J B. Comprehensive left ventricular outflow tract management beyond septal reduction to relieve obstruction[J]. Asian Cardiovasc Thorac Ann, 2022, 30(1): 43-52. DOI: 10.1177/02184923211034689.

[38]

RAM E, SCHWAMMENTHAL E, KUPERSTEIN R, et al. Secondary chordal resection with septal myectomy for treatment of symptomatic obstructive hypertrophic cardiomyopathy[J]. Eur J Cardiothorac Surg, 2021, 60(3): 699-707. DOI: 10.1093/ejcts/ezab116.

[39]

HAMMAMI R, KAMMOUN A, HASSINE M, et al. Hypertrophic obstructive cardiomyopathy with left ventricle outflow tract chordae insertion: Surgery or alcohol septal ablation A case report[J/OL]. Clin Case Rep, 2023, 11(9): e7928 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/37744623/. DOI: 10.1002/ccr3.7928.

[40]

YASIN A, TRONGTORSAK A, SHAH S, et al. Aberrant chordae tendineae causing transient left ventricular outflow tract obstruction in hypertrophic cardiomyopathy[J/OL]. J Am Coll Cardiol, 2024, 83(13): 4218 [2025-12-28]. https://www.jacc.org/doi/10.1016/S0735-1097(24)06208-9. DOI: 10.1016/S0735-1097(24)06208-9.

[41]

KADKHODAYAN A, SCHAFF H V, ELEID M F. Anomalous papillary muscle insertion in hypertrophic cardiomyopathy[J/OL]. Eur Heart J Cardiovasc Imaging, 2016, 17(5): 588 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/26864188/. DOI: 10.1093/ehjci/jew007.

[42]

CITTADINI F, OLIVA A, ARENA V, et al. Sudden cardiac death due to an anomalous posterior papillary muscle[J]. Am J Forensic Med Pathol, 2011, 32(3): 239-241. DOI: 10.1097/PAF.0b013e3181d3ca7e.

[43]

RAFFA G M, ROMANO G, TURRISI M, et al. Pathoanatomic findings and treatment during hypertrophic obstructive cardiomyopathy surgery: the role of mitral valve[J]. Heart Lung Circ, 2019, 28(3): 477-485. DOI: 10.1016/j.hlc.2018.02.006.

[44]

The Joint Committee of Cardiomyopathy Specialty Alliance, National Center for Cardiovascular Diseases/Cardiovascular Precision Medicine Branch of China International Exchange and Promotive Association for Medical and Health Care. "2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy". 2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy[J]. Chinese Circulation Journal. 2023. 38(1): 1-33. DOI: 10.3969/j.issn.1000-3614.2023.01.001

[45]

BERG J J, ECKSTEIN J, DEUTSCH M A, et al. Resection of hypertrophic papillary muscles and mitral valve replacement in a patient with midventricular hypertrophic obstructive cardiomyopathy - a new approach[J/OL]. J Cardiothorac Surg, 2024, 19(1): 105 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/38388907/. DOI: 10.1186/s13019-024-02529-w.

[46]

WONG L Y, VILA R, LANTZ G, et al. Midterm outcomes: a comprehensive approach to surgery for hypertrophic obstructive cardiomyopathy[J]. Ann Thorac Surg, 2024, 118(3): 597-603. DOI: 10.1016/j.athoracsur.2024.05.024.

[47]

KAWAGOE K, FURUKAWA K, ISHI H, et al. Surgical management of hypertrophic obstructive cardiomyopathy with anomalous papillary muscle: a case report[J]. J Cardiol Cases, 2025, 31(4): 101-104. DOI: 10.1016/j.jccase.2024.12.006.

[48]

GILREATH K, SAWMA T, SCHAFF H, et al. Abstract 4363343: papillary muscle anatomy in hypertrophic cardiomyopathy: comparison to normal and impact on outcomes of septal myectomy[J/OL]. Circulation, 2025, 152(Suppl_3) [2025-12-28]. https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4363343. DOI: 10.1161/circ.152.suppl_3.4363343.

[49]

LEKOVIĆ A, ŽIVKOVIĆ V, NIKOLIĆ S. Anomalous papillary muscle insertion into mitral valve leaflet: Autopsy study and implications[J]. J Forensic Sci, 2023, 68(1): 176-184. DOI: 10.1111/1556-4029.15182.

[50]

GÜVEN B, CAN T S, DENIZ M F, et al. Evaluation of potential links between phenotypic features and genetic variants in left ventricular outflow tract obstruction in hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging[J]. Int J Cardiovasc Imaging, 2024, 40(11): 2417-2428. DOI: 10.1007/s10554-024-03250-4.

[51]

ZHANG J, DENG Y B, TANG Q Y, et al. Evaluation of left ventricular systolic function in different layers myocardium in patients with hypertrophic cardiomyopathy by two-dimensional speckle tracking echocardiography[J]. Chin J Ultrason, 2015, 24(4): 277-281. DOI: 10.3760/cmaj.i.ssn1.004-44772.0150.40.01.

[52]

HODGES K, RIVAS C G, AGUILERA J, et al. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center[J]. J Thorac Cardiovasc Surg, 2019, 157(6): 2289-2299. DOI: 10.1016/j.jtcvs.2018.11.148.

[53]

SCHLITTLER M, PRAMSTALLER P P, ROSSINI A, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: a perspective from fibroblasts[J/OL]. Int J Mol Sci, 2023, 24(19): 14845 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/37834293/. DOI: 10.3390/ijms241914845.

[54]

SKÓRKA P, PIOTROWSKI J, BAKINOWSKA E, et al. The role of signalling pathways in myocardial fibrosis in hypertrophic cardiomyopathy[J/OL]. Rev Cardiovasc Med, 2025, 26(2): 27152 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/40026508/. DOI: 10.31083/RCM27152.

[55]

MURTHI S RAJ, PETRY A, SHASHIKADZE B, et al. Contribution of hypoxia-inducible factor 1alpha to pathogenesis of sarcomeric hypertrophic cardiomyopathy[J/OL]. Sci Rep, 2025, 15(1): 2132 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/39820339/. DOI: 10.1038/s41598-025-85187-9.

[56]

KAMP N J, CHERY G, KOSINSKI A S, et al. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis[J/OL]. Prog Cardiovasc Dis, 2021, 66: 10-16 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/33171204/. DOI: 10.1016/j.pcad.2020.11.001.

[57]

NAKAMORI S, ROWIN E J, JAAFAR N, et al. Abstract 16842: progression of myocardial fibrosis in hypertrophic cardiomyopathy[J/OL]. Circulation, 2023, 148(Suppl_1) [2025-12-28]. https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.16842. DOI: 10.1161/circ.148.suppl_1.16842.

[58]

ONG L T, FAN S W D. Prevalence and clinical significance of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy: a systematic review and meta-analysis[J]. Cardiol Young, 2024, 34(7): 1456-1465. DOI: 10.1017/S1047951124000337.

[59]

KIAOS A, DASKALOPOULOS G N, KAMPERIDIS V, et al. Quantitative late gadolinium enhancement cardiac magnetic resonance and sudden death in hypertrophic cardiomyopathy: a meta-analysis[J]. JACC Cardiovasc Imaging, 2024, 17(5): 489-497. DOI: 10.1016/j.jcmg.2023.07.005.

[60]

TONDI D, STURLA F, MARIN-CUARTAS M, et al. Magnetic resonance-based computational modelling of healthy and prolapsing mitral valves to quantify the load transfer between the mitral apparatus and the ventricular myocardium[J/OL]. Comput Methods Programs Biomed, 2026, 274: 109151 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/41265362/. DOI: 10.1016/j.cmpb.2025.109151.

[61]

KOO H J, LEE S A, JUNG S H, et al. Tailored planning of surgical myectomy in obstructive hypertrophic cardiomyopathy[J/OL]. Radiographics, 2024, 44(1): e230050 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/38060425/. DOI: 10.1148/rg.230050.

[62]

BAESSATO F, FUSINI L, MURATORI M, et al. Echocardiography vs. CMR in the quantification of chronic mitral regurgitation: a happy marriage or stormy divorce [J/OL]. J Cardiovasc Dev Dis, 2023, 10(4): 150 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/37103029/. DOI: 10.3390/jcdd10040150.

[63]

GARG P, PAVON A G, PENICKA M, et al. Cardiovascular magnetic resonance imaging in mitral valve disease[J]. Eur Heart J, 2025, 46(7): 606-619. DOI: 10.1093/eurheartj/ehae801.

[64]

BOTIS I, BAZMPANI M A, DAIOS S, et al. The role of cardiovascular magnetic resonance imaging in the assessment of mitral regurgitation[J/OL]. Diagnostics (Basel), 2024, 14(6): 644 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/38535064/. DOI: 10.3390/diagnostics14060644.

[65]

TONDI L, DISABATO G, D'ANDRIA P, et al. Cardiovascular magnetic resonance insights into anomalies of the mitral valve apparatus in Fabry cardiomyopathy and hypertrophic cardiomyopathy[J/OL]. Front Cardiovasc Med, 2024, 11: 1458705 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/39411176/. DOI: 10.3389/fcvm.2024.1458705.

[66]

PUGLIESE L, LUCIANO A, CHIOCCHI M. The role of cardiac magnetic resonance imaging in the management of hypertrophic cardiomyopathy[J/OL]. J Cardiovasc Dev Dis, 2025, 12(5): 189 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/40422960/. DOI: 10.3390/jcdd12050189.

[67]

ROWIN E J, MARON B J, MARON M S. The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging: clinical and etiologic implications[J]. JACC Cardiovasc Imaging, 2020, 13(9): 2002-2016. DOI: 10.1016/j.jcmg.2019.09.020.

[68]

PAVON A G, GUGLIELMO M, MENNILLI P M, et al. The role of cardiovascular magnetic resonance in patients with mitral regurgitation[J/OL]. J Cardiovasc Dev Dis, 2022, 9(11): 399 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/36421934/. DOI: 10.3390/jcdd9110399.

[69]

MYERSON S G, D'ARCY J, CHRISTIANSEN J P, et al. Determination of clinical outcome in mitral regurgitation with cardiovascular magnetic resonance quantification[J]. Circulation, 2016, 133(23): 2287-2296. DOI: 10.1161/CIRCULATIONAHA.115.017888.

[70]

MAHER T, VEGH A, URETSKY S. Mitral regurgitation: advanced imaging parameters and changing treatment landscape[J]. Heart Fail Clin, 2023, 19(4): 525-530. DOI: 10.1016/j.hfc.2023.05.001.

[71]

GARG P, SWIFT A J, ZHONG L, et al. Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging[J]. Nat Rev Cardiol, 2020, 17(5): 298-312. DOI: 10.1038/s41569-019-0305-z.

[72]

COISNE A, LANCELLOTTI P, HABIB G, et al. ACC/AHA and ESC/EACTS guidelines for the management of valvular heart diseases JACC guideline comparison[J]. J Am Coll Cardiol, 2023, 82(8): 721-734. DOI: 10.1016/j.jacc.2023.05.061.

[73]

THOMPSON A, FLEISCHMANN K E, SMILOWITZ N R, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J/OL]. Circulation, 2024, 150(19) [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/39316661/. DOI: 10.1161/cir.0000000000001285.

[74]

GUPTA A N, AVERY R, SOULAT G, et al. Direct mitral regurgitation quantification in hypertrophic cardiomyopathy using 4D flow CMR jet tracking: evaluation in comparison to conventional CMR[J/OL]. J Cardiovasc Magn Reson, 2021, 23(1): 138 [2025-12-28]. https://pubmed.ncbi.nlm.nih.gov/34865629/. DOI: 10.1186/s12968-021-00828-y.

[75]

LEE J, GUPTA A N, MA L E, et al. Valvular regurgitation flow jet assessment using in vitro 4D flow MRI: Implication for mitral regurgitation[J]. Magn Reson Med, 2022, 87(4): 1923-1937. DOI: 10.1002/mrm.29082.

[76]

YU M R, ZHANG D F, ZENG W, et al. Advances in the application of artificial intelligence in multimodality cardiac imaging[J]. J Clin Cardiol, 2023, 39(12): 922-929. DOI: 10.13201/j.issn.1001-1439.2023.12.005.

[77]

XIE M X. Artificial intelligence in medical imaging: implications for interventional therapy of heart valve diseases[J]. J Clin Cardiol, 2022, 38(12): 929-933, 940. DOI: 10.13201/j.issn.1001-1439.2022.12.001.

[78]

WANG J A. Artificial intelligence enhances imaging assessment in cardiovascular diseases,[J]. Chin J Cardiovasc Med, 2025, 30(2): 121-122. DOI: 10.3969/j.issn.1007-5410.2025.02.001.

PREV Advances in metabolic imaging technology for nasopharyngeal carcinoma: From mechanisms to applications

NEXT Research progress of multi-parameter MRI and radiomics in distinguishing HER-2-low and HER-2-zero expressing breast cancer

LINK

Tel & Fax: +8610-67113815 E-mail: editor@cjmri.cn